Maravai LifeSciences Holdings, Inc.
MRVI
$1.77
$0.052.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 259.19M | 276.92M | 278.59M | 274.10M | 288.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 259.19M | 276.92M | 278.59M | 274.10M | 288.95M |
| Cost of Revenue | 150.88M | 148.54M | 148.40M | 153.40M | 148.74M |
| Gross Profit | 108.31M | 128.38M | 130.19M | 120.70M | 140.20M |
| SG&A Expenses | 161.77M | 154.91M | 154.68M | 149.50M | 147.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 331.87M | 322.70M | 322.34M | 321.07M | 313.31M |
| Operating Income | -72.68M | -45.78M | -43.76M | -46.97M | -24.37M |
| Income Before Tax | -261.48M | 441.21M | 596.29M | 599.85M | 617.74M |
| Income Tax Expenses | -1.86M | 764.32M | 758.54M | 759.56M | 756.11M |
| Earnings from Continuing Operations | -259.62 | -323.11 | -162.26 | -159.71 | -138.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 114.78M | 98.45M | 30.17M | 28.67M | 19.35M |
| Net Income | -144.85M | -224.66M | -132.08M | -131.04M | -119.03M |
| EBIT | -72.68M | -45.78M | -43.76M | -46.97M | -24.37M |
| EBITDA | -24.30M | 1.04M | 2.07M | -3.91M | 15.89M |
| EPS Basic | -1.03 | -1.65 | -1.00 | -0.99 | -0.90 |
| Normalized Basic EPS | 0.39 | 3.55 | 3.08 | 3.08 | 3.10 |
| EPS Diluted | -1.03 | -1.65 | -1.00 | -0.99 | -0.90 |
| Normalized Diluted EPS | 0.39 | 3.55 | 3.08 | 3.08 | 3.10 |
| Average Basic Shares Outstanding | 551.54M | 541.87M | 532.25M | 528.27M | 527.67M |
| Average Diluted Shares Outstanding | 551.54M | 541.87M | 532.25M | 528.27M | 527.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |